Ascent (ACNT) Q4 2022: Munhall Losses Drive $8.9M Hit, Chemicals Set for Expansion

March 31, 2023 | By EarningsIQ Research

Ascent’s fourth quarter was defined by a decisive exit from its underperforming galvanized business, resulting in a sharp $8.9 million loss at the Munhall facility and a near-term drag on consolidated results. Management’s focus now shifts to scaling specialty chemicals, which demonstrated resilience and is positioned as the company’s primary growth engine. With legacy headwinds addressed, Ascent expects margin normalization and renewed free cash flow as it reallocates capital to higher-return segments in 2023.

Summary

• Galvanized Exit Reshapes Earnings Base: Divestment of Munhall’s low-margin operation clarifies future profitability.
• Chemicals Ascend as Strategic Priority: Specialty chemicals segment is now the central platform for growth and margin stability.
• Free Cash Flow and Margin Recovery Ahead: Management signals improved operational efficiency and capital discipline for 2023.

Business Overview

Ascent is a diversified manufacturer operating through two primary segments: tubular products, which includes stainless pipe and tube, and specialty chemicals, focused on contract manufacturing for industrial customers. The company generates revenue from product sales and long-term customer contracts across these segments, with a strategic shift underway to emphasize higher-margin, less cyclical specialty chemicals over legacy commodity tubular products.

Performance Analysis

Fourth quarter results were heavily impacted by the company’s decision to exit the galvanized product line at its Munhall facility, resulting in a significant net loss and negative adjusted EBITDA for the segment. Excluding Munhall, underlying business margin performance was consistent with prior quarters, reflecting the core earnings power of the ongoing operations. The specialty chemical segment delivered year-over-year revenue growth and stable earnings, offsetting some of the tubular segment’s volatility.

Full year results showed top-line growth driven by favorable pricing in the first half, but gross margin compressed due to elevated input costs and a shift away from lower-return product lines. The company’s net leverage improved materially as management prioritized deleveraging and disciplined capital allocation, including targeted share repurchases and a pause on aggressive M&A amid an unfavorable deal environment.

• Munhall Drag Isolated: $8.9 million net loss and $7.4 million negative adjusted EBITDA at Munhall masked normalized margin trends elsewhere in the business.
• Chemical Segment Resilience: Despite industry destocking, specialty chemicals posted stable earnings and expanded its customer pipeline.
• Inventory and Cost Controls: Stabilized pricing and tighter inventory management set the stage for working capital release in 2023.

With the galvanized exit behind it, Ascent’s core business now reflects a more predictable earnings and cash flow profile, especially as the chemical segment’s contribution grows.

Executive Commentary

Strategic Positioning

1. Galvanized Business Exit and Resource Reallocation

Ascent’s strategic withdrawal from galvanized production at Munhall marks a clear pivot away from commodity exposure, freeing up capital and operational focus for higher-return segments. This move addresses a persistent margin drag and reduces volatility tied to import competition and working capital intensity.

2. Specialty Chemicals as Growth Platform

The specialty chemicals segment is now prioritized as the company’s primary engine for growth and margin stability. Management aims to leverage longer-term contracts, improved sales strategy, and targeted M&A to expand this segment, capitalizing on its resilience and less cyclical demand profile.

3. Disciplined Capital Allocation and M&A Approach

Ascent maintained a conservative posture on acquisitions in 2022, eschewing deals at inflated multiples and instead focusing on organic improvement and opportunistic share repurchases. Management signals a readiness to pursue M&A as deal valuations normalize, but only where fit and underwriting standards are met.

4. Operational Efficiency and Working Capital Release

With stabilized pricing and improved inventory management, Ascent expects to unlock working capital for redeployment, supporting infrastructure, automation, and high-return projects in core segments.

Key Considerations

This quarter’s results provide a clean break from legacy underperformance, but also highlight the importance of execution as Ascent transitions to a more focused, higher-margin portfolio.

Key Considerations:

• Galvanized Exit Creates Near-Term Noise: Reported losses obscure underlying margin improvement and reset the base for future comparisons.
• Chemicals Segment Visibility: Extended sales cycles and customer stickiness position chemicals for durable growth, but require patience for ramp-up.
• Capital Deployment Discipline: Share repurchases signal undervaluation, but future M&A will need to deliver on promised synergies and margin expansion.
• Operational Focus Post-Transition: Execution risk remains as resources shift and new processes are embedded in the core business.

Risks

Ascent’s transition exposes it to execution risk as it reallocates resources and integrates new business models, especially in chemicals where sales cycles are long and customer wins can be lumpy. Macro uncertainty, raw material inflation, and potential delays in working capital release may pressure near-term results. Competitive dynamics in both core and target markets remain a watchpoint, particularly as the company seeks to scale specialty chemicals through both organic and inorganic means.

Forward Outlook

For Q1 2023, Ascent expects:

• Residual minor impacts from inventory buys and Munhall-related costs, with normalization by Q2.
• Resumption of free cash flow generation and a return to adjusted EBITDA margins north of 10% on a consolidated basis by mid-year.

For full-year 2023, management anticipates:

• Stronger back half as galvanized exit benefits flow through and chemicals growth accelerates.

Management highlighted several factors that will shape results:

• Continued focus on reallocating capital to high-return segments and projects.
• Opportunistic approach to M&A as market conditions improve.

Takeaways

Ascent’s Q4 marks a strategic inflection, with the galvanized exit clarifying the company’s core earnings power and setting the stage for a more predictable, higher-margin future.

• Galvanized Drag Removed: The Munhall exit removes a key source of volatility and positions the company for steadier margin performance.
• Chemicals Platform in Focus: Specialty chemicals now anchors the growth narrative, with management intent on scaling through both organic and M&A-driven initiatives.
• Execution and Discipline Required: Investors should monitor the pace of margin normalization, working capital release, and the success of capital redeployment in 2023.

Conclusion

Ascent’s decisive pivot away from its legacy galvanized business clarifies its earnings base and strategic direction. With chemicals now at the center of its growth plan and a renewed focus on operational discipline, the company is positioned for margin recovery and improved cash flow in 2023, but must deliver on execution as it transitions to a more focused portfolio.

Industry Read-Through

Ascent’s galvanized exit and chemicals pivot are emblematic of broader trends among industrial manufacturers seeking margin stability and reduced commodity exposure. The move away from low-value-added, import-exposed products reflects a sector-wide emphasis on specialty, contract-based revenue streams with greater pricing power and resilience. For peers in metals and chemicals, the quarter signals that capital discipline and portfolio reshaping are increasingly rewarded, while legacy drag remains a risk to margin and valuation. As M&A markets normalize, expect a renewed focus on selective, accretive deals in specialty manufacturing across the industry.

ACNT Industrials Manufacturing Chemicals Tubular Products Portfolio Restructuring Capital Allocation